QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

RDY

QT60Dr. Reddy's Laboratories Limited
NYSE·Healthcare·Drug Manufacturers - Specialty & Generic·IN
Latest market price
13.29
+0.14+1.06%
OverviewShort InterestFilings
RDYQT60Dr. Reddy's Laboratories Limited·NYSE
OverviewShort InterestFilings
13.29+1.06%
TA
Loading chart...
Screen all →
TAK+1.36%$15.63HLN+1.01%$8.96TEVA-3.32%$31.48VTRS-2.29%$15.37ELAN+3.55%$24.22RGC-18.96%$12.01LNTH+0.65%$103.86AMRX-0.43%$16.21
Snapshot
Index-P/E24.66EPS (ttm)
0.59
Insider Own-
Shs Outstand832.70M
Perf Week-0.52%
Market Cap11.19BForward P/E20.45EPS next Y0.65Insider Trans-Shs Float-Perf Month-1.19%
Enterprise Value11.98BPEG-EPS next Q0.00Inst Own-Short Float-Perf Quarter-6.01%
Income453.16MP/S3.14EPS this Y-10.68%Inst Trans-Short Ratio-Perf Half Y-4.46%
Sales3.56BP/B2.80EPS next Y23.31%ROA7.40%Short Interest-Perf YTD-5.34%
Book/sh4.79P/C19.09EPS next 5Y21.84%ROE11.76%52W High15.71 -15.40%Perf Year-12.85%
Cash/sh1.11P/FCF44.31EPS past 3/5Y-ROIC8.07%52W Low12.19 9.02%Perf 3Y-
Dividend Est.0.06 (0.48%)EV/EBITDA14.71Sales past 3/5Y9.37% 159.50%Gross Margin52.77%Volatility0.96% 1.13%Perf 5Y-
Dividend TTM0.09 (0.69%)EV/Sales3.36EPS Y/Y TTM-16.39%Oper. Margin14.79%ATR (14)0.24Perf 10Y-
Dividend Ex-DateJul 09, 2026Quick Ratio1.35Sales Y/Y TTM-0.70%Profit Margin12.76%RSI (14)48.56Recom2.67
Dividend Gr. 3/5Y6.56% 6.75%Current Ratio1.80EPS Q/Q-SMA20-0.47%Beta0.35Target Price-
Payout15.54%Debt/Eq0.24Sales Q/Q-14.88%SMA50-0.44%Rel Volume0.76Prev Close13.15
Employees27,048LT Debt/Eq0.03EarningsJul 22SMA200-4.04%Avg Volume2.34MPrice13.29
IPO DateApr 11, 2001Option/ShortYes / YesEPS/Sales Surpr.-33.33% -11.39%Net Debt/EBITDA0.97Volume1,782,542Change1.06%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-05-25UpgradeHSBCHold → Buy
Feb-02-21UpgradeBarclaysEqual Weight → Overweight
Jan-09-20UpgradeCitigroupSell → Buy
Nov-04-19DowngradeBank of AmericaBuy → Neutral
Nov-04-19DowngradeB of A SecuritiesBuy → Neutral
Sep-04-19UpgradeCredit SuisseUnderperform → Outperform
May-20-19DowngradeMorgan StanleyOverweight → Equal Weight
Sep-21-17UpgradeMorgan StanleyEqual Weight → Overweight
Jul-27-16DowngradeJefferiesHold → Underperform
Jul-27-16DowngradeHSBCHold → Reduce
Latest News
Jun-16-26
Jun-16-2608:05AM
Innoviva Specialty Therapeutics Inks Agreement With Dr. Reddy's Laboratories To Develop, Commercialize XACDURO To Treat Bacterial PneumoniaBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2026
3/31/2026
FY 2025
3/31/2025
FY 2024
3/31/2024
FY 2023
3/31/2023
FY 2022
3/31/2022
FY 2021
3/31/2021
FY 2020
3/31/2020
FY 2019
3/31/2019
Total Revenue3,8224,0013,849
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A1,8011,8901,598
Gross Profit2,0202,1112,252
Selling, General and Administrative Excl. Other1,1841,2721,110
Research and Development274287324
Other Operating Expense-8-1-32
Operating Income570553850
Interest Expense434533
Unusual Expense
———
Non-Operating Income (Expense)-80-144-92
Net Income Before Taxes628653908
Income Taxes143147231
Consolidated Net Income491510669
Net Income From Continuing Operations487506677
Net Income491510669
EPS (Recurring)0.590.610.80
EPS (Basic, Before Extraordinaries)0.590.610.80
EPS (Diluted)0.590.610.80
EBITDA8839431,143
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio22.5322.69—
Price To Sales Ratio2.902.88—
Gross Margin52.8552.7658.51
Operating Margin14.9113.8222.08
Net Margin12.8512.7517.38
Shares Outstanding835832833
Market Capitalization11,09711,523—
Operating Lease Expense
———
Insider Trading Volume
$14.37$13.72$13.06$12.40$11.75● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR